The tumor vasculature an attractive CAR T cell target in solid tumors

T cell engineered with a novel nanobody‐based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy

(2019) Fatemeh Hajari Taheri et al.   IUBMB LIFE

Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells

(2019) Esther Drent et al.   CLINICAL CANCER RESEARCH

Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice

(2019) Yushu Joy Xie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don’t Forget the Fuel

(2017) Melita Irving et al.   Frontiers in Immunology

T Cells Bearing a Chimeric Antigen Receptor against Prostate-Specific Membrane Antigen Mediate Vascular Disruption and Result in Tumor Regression

(2014) S. P. Santoro et al.   Cancer Immunology Research

Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice

(2010) Dhanalakshmi Chinnasamy et al.   JOURNAL OF CLINICAL INVESTIGATION